ResearcherUniversity of MiamiActive in the last 2 years
Christine Isabelle Rafie
Matched on ORCID iD 0000-0002-2917-7016; OpenAlex author ID A5081698614; NIH RePORTER profile ID 16244386. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 1
- Labs led
- 0
- Collaborators
- 17
2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 grant
Papers 3
- Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invigorate antitumor immunity in pancreatic c… Co-author DOI 10.1007/s00262-025-04096-y↗
- Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-1046↗
- Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer. Co-author DOI 10.1038/s41388-022-02368-w↗
Grants 1
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Iago De Castro Silva · 3 shared papers, 2022–2025 · strength 0.46
- Paper Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invig… DOI 10.1007/s00262-025-04096-y↗
- Paper Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreati… DOI 10.1158/2159-8290.cd-22-1046↗
- Paper Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53… DOI 10.1038/s41388-022-02368-w↗
- Nilesh Deshpande · 3 shared papers, 2022–2025 · strength 0.46
- Paper Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invig… DOI 10.1007/s00262-025-04096-y↗
- Paper Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreati… DOI 10.1158/2159-8290.cd-22-1046↗
- Paper Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53… DOI 10.1038/s41388-022-02368-w↗
- Siddharth Mehra · 3 shared papers, 2022–2025 · strength 0.46
- Paper Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invig… DOI 10.1007/s00262-025-04096-y↗
- Paper Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreati… DOI 10.1158/2159-8290.cd-22-1046↗
- Paper Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53… DOI 10.1038/s41388-022-02368-w↗
- Nipun B. Merchant · 3 shared papers, 2022–2025 · strength 0.46
- Paper Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invig… DOI 10.1007/s00262-025-04096-y↗
- Paper Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreati… DOI 10.1158/2159-8290.cd-22-1046↗
- Paper Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53… DOI 10.1038/s41388-022-02368-w↗
- Nagaraj S. Nagathihalli · 3 shared papers, 2022–2025 · strength 0.46
- Paper Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invig… DOI 10.1007/s00262-025-04096-y↗
- Paper Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreati… DOI 10.1158/2159-8290.cd-22-1046↗
- Paper Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53… DOI 10.1038/s41388-022-02368-w↗
- Ifeanyichukwu Chinedu Ogobuiro · 2 shared papers, 2023–2025 · strength 0.34
- Paper Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invig… DOI 10.1007/s00262-025-04096-y↗
- Paper Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreati… DOI 10.1158/2159-8290.cd-22-1046↗
- Haleh Amirian · 2 shared papers, 2023–2025 · strength 0.34
- Paper Cell-specific nanoengineering strategy to disrupt tolerogenic signaling from myeloid-derived suppressor cells and invig… DOI 10.1007/s00262-025-04096-y↗
- Paper Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreati… DOI 10.1158/2159-8290.cd-22-1046↗
- Austin R. Dosch · 2 shared papers, 2022–2023 · strength 0.24
- Paper Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreati… DOI 10.1158/2159-8290.cd-22-1046↗
- Paper Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53… DOI 10.1038/s41388-022-02368-w↗
- Samara P. Singh · 2 shared papers, 2022–2023 · strength 0.24
- Paper Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreati… DOI 10.1158/2159-8290.cd-22-1046↗
- Paper Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53… DOI 10.1038/s41388-022-02368-w↗
- Jashodeep Datta · 2 shared papers, 2022–2023 · strength 0.24
- Paper Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreati… DOI 10.1158/2159-8290.cd-22-1046↗
- Paper Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53… DOI 10.1038/s41388-022-02368-w↗
- Jashodeep Datta · 1 shared paper, 2025 · strength 0.22
- William L. Hwang · 1 shared paper, 2023 · strength 0.12
- Anna Bianchi · 1 shared paper, 2023 · strength 0.12
- Carina Shiau · 1 shared paper, 2023 · strength 0.12
- Ben Z. Stanger · 1 shared paper, 2023 · strength 0.12
- Prateek Sharma · 1 shared paper, 2022 · strength 0.12
- Peter J. Hosein · 1 shared paper, 2022 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.